New York, New York - October 3, 2012 (www.investorideas.com newswire) Investorideas.com staff: Investorideas.com, an investor research portal specializing in sector for independent investors issues a trading alert for NASDAQ’s top percentage gainer, Sarepta Therapeutics (NASDAQ:SRPT), up a whopping 182% . The stock is trading at $42.32, moving 27.33 or 182.32% as of 2:25PM EDT on over 23 Million shares.

The Company today reported that treatment with its lead exon-skipping compound, eteplirsen, met the primary efficacy endpoint, increase in novel dystrophin, and achieved a significant clinical benefit on the primary clinical outcome, the 6-minute walk test (6MWT) over the placebo/delayed treatment cohort in a Phase IIb extension trial in Duchenne muscular dystrophy (DMD) patients.

Read more: NASDAQ Top Gainer Sarepta Therapeutics (NASDAQ:SRPT) Spikes 182%

New York, New York - October 3, 2012 (Investorideas.com water newswire, www.water-stocks.com) Investorideas.com staff: Investorideas.com, an investor research portal specializing in sector for independent investors has updated its fourteen global stock directories for October. Smart money is looking at water stocks but there are winners in every sector and sometimes within the small and microcap stocks.

In a recent Investorideas.com article , water investment expert Neil Berlant named his potential long term beneficiaries based on global drought conditions: "BMI, CCC, ERII, HEK, ITRI, LAYN, LNN, MWA, NWPX, TTC, VMI." http://www.investorideas.com/news/2012/water/09281.asp

Read more: How to Find the next potential big stock winner in your favorite sector!

SAN DIEGO - October 3, 2012 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), today released the slide-deck underlying a presentation given yesterday by its Chairman and CEO, Jim Joyce at the EXOSOMES & MICROVESICLES 2012 conference in Orlando, Florida. The presentation was entitled: Extracorporeal clearance of tumor-secreted exosomes as an adjunct to enhance cancer therapy efficacy.

Investorideas.com Newswire

The presentation focused on the potential of the Aethlon Hemopurifier® to be combined with chemo and immunotherapies as a strategy to enhance cancer therapy outcomes. The Hemopurifier®, which is a first-in-class device being advanced in Hepatitis C (HCV) care, has also demonstrated the ability to capture cancer-promoting exosomes secreted by tumors.

Read more: Biotech Stock News; Aethlon Medical (OTCBB: AEMD) Releases EXOSOMES & MICROVESICLES 2012...

New York, NY-October 2 , 2012 (www.Investorideas.com Newswire, www.techsectorstocks.com ) Investor Ideas,, a global investor research portal for independent investors, issues a tech stock trading alert for  Research In Motion Limited (NASDAQ: RIMM), (TSX:RIM) .

The stock made the top ten traders list on the TSX, trading at $ 8.240, up 0.550 or 7.15% on 5,781,777 shares.

The company reported second quarter earnings last week.

Read more: TSX Tech Stock Trading Alert: Research In Motion (TSX: RIM) Makes Top Trading List

New York, NY - October 1, 2012 (Investorideas.com Newswire, www.biodefensestocks.com) Investorideas.com, a leader in research for independent investors issues a trading alert for biodefense stock, PositiveID Corporation (OTCBB: PSID), trading up at $0.0260, gaining 0.0035 or 15.56% as of 11:16AM EDT on over 758,000 shares. The stock had a morning high of $0.0270.

Last week the Company released an update to shareholders on its pursuit of BioWatch Generation 3, Phase II. Two weeks ago, the Department of Homeland Security ("DHS") revised its procurement strategy for BioWatch Generation 3, Phase II, which now will consist of a two-stage procurement which includes two to three years of testing estimated at $89 million.

Read more: Biodefense Stock Trading Alert: PositiveID (OTCBB: PSID) Up 15%